Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2017
At a glance
- Drugs CJM 112 (Primary) ; LCL 161 (Primary) ; Spartalizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 08 Aug 2017 Planned End Date changed from 24 Dec 2018 to 1 Jun 2020.
- 08 Aug 2017 Planned primary completion date changed from 24 Dec 2018 to 1 Jun 2020.
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.